{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:21:16Z","timestamp":1790716876067,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T00:00:00Z","timestamp":1529625600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003500","name":"University of Padova","doi-asserted-by":"crossref","award":["DOR1721185\/17"],"award-info":[{"award-number":["DOR1721185\/17"]}],"id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Istituto Oncologico Veneto IRCCS","award":["L02P28"],"award-info":[{"award-number":["L02P28"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13058-018-1003-1","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T22:15:20Z","timestamp":1529619320000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Immune characterization of breast cancer metastases: prognostic implications"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3967-9861","authenticated-orcid":false,"given":"Maria Vittoria","family":"Dieci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilena","family":"Tsvetkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Orvieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Piacentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Ficarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Griguolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Miglietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Giarratano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Omarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Bonaguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Cappellesso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Vernaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Alberto","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Faggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Tasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierfranco","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,22]]},"reference":[{"issue":"4","key":"1003_CR1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","volume":"13","author":"P Savas","year":"2016","unstructured":"Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13(4):228\u201341.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"1003_CR2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/annonc\/mdt556","volume":"25","author":"MV Dieci","year":"2014","unstructured":"Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25(3):611\u20138.","journal-title":"Ann Oncol"},{"issue":"2","key":"1003_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann Oncol. 2015;26(2):259\u201371.","journal-title":"Ann Oncol"},{"issue":"7","key":"1003_CR4","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","volume":"31","author":"S Loi","year":"2013","unstructured":"Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860\u20137.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1003_CR5","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","volume":"25","author":"S Loi","year":"2014","unstructured":"Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25(8):1544\u201350.","journal-title":"Ann Oncol"},{"issue":"1","key":"1003_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamaoncol.2015.3239","volume":"2","author":"EA Perez","year":"2016","unstructured":"Perez EA, Ballman KV, Tenner KS, Thompson EA, Badve SS, Bailey H, et al. Association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer. JAMA Oncol. 2016;2(1):56\u201364.","journal-title":"JAMA Oncol."},{"issue":"27","key":"1003_CR7","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","volume":"32","author":"S Adams","year":"2014","unstructured":"Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncologia. 2014;32(27):2959\u201366.","journal-title":"J Clin Oncologia"},{"issue":"8","key":"1003_CR8","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1093\/annonc\/mdv239","volume":"26","author":"MV Dieci","year":"2015","unstructured":"Dieci MV, Mathieu MC, Guarneri V, Conte P, Delaloge S, Andre F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol. 2015;26(8):1698\u2013704.","journal-title":"Ann Oncol"},{"key":"1003_CR9","doi-asserted-by":"crossref","unstructured":"Dieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, et al. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the international Immuno-oncology biomarker working group on breast cancer. Semin Cancer Biol. 2017.","DOI":"10.1016\/j.semcancer.2017.10.003"},{"issue":"1","key":"1003_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","volume":"28","author":"C Denkert","year":"2010","unstructured":"Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105\u201313.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1003_CR11","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/jamaoncol.2015.0830","volume":"1","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol. 2015;1(4):448\u201354.","journal-title":"JAMA Oncol."},{"issue":"12","key":"1003_CR12","doi-asserted-by":"publisher","first-page":"e79775","DOI":"10.1371\/journal.pone.0079775","volume":"8","author":"Y Issa-Nummer","year":"2013","unstructured":"Issa-Nummer Y, Darb-Esfahani S, Loibl S, Kunz G, Nekljudova V, Schrader I, et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial. PLoS One. 2013;8(12):e79775.","journal-title":"PLoS One"},{"issue":"10","key":"1003_CR13","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1093\/annonc\/mdw262","volume":"27","author":"MV Dieci","year":"2016","unstructured":"Dieci MV, Prat A, Tagliafico E, Pare L, Ficarra G, Bisagni G, et al. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. Ann Oncol. 2016;27(10):1867\u201373.","journal-title":"Ann Oncol"},{"issue":"6","key":"1003_CR14","doi-asserted-by":"publisher","first-page":"R126","DOI":"10.1186\/bcr3072","volume":"13","author":"NR West","year":"2011","unstructured":"West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011;13(6):R126.","journal-title":"Breast Cancer Res"},{"key":"1003_CR15","volume-title":"Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy","author":"C Denkert","year":"2016","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, Ingold Heppner B, Klauschen F, Furlanetto F, et al. Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy. Abstract S1-09. Presented at SABCS2016, San Antonio, TX, USA, 2016."},{"issue":"1","key":"1003_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S1470-2045(16)30631-3","volume":"18","author":"SJ Luen","year":"2017","unstructured":"Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, et al. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol. 2017;18(1):52\u201362.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1003_CR17","doi-asserted-by":"publisher","first-page":"e172085","DOI":"10.1001\/jamaoncol.2017.2085","volume":"3","author":"S Liu","year":"2017","unstructured":"Liu S, Chen B, Burugu S, Leung S, Gao D, Virk S, et al. Role of cytotoxic tumor-infiltrating lymphocytes in predicting outcomes in metastatic HER2-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2017;3(11):e172085.","journal-title":"JAMA Oncol"},{"issue":"10","key":"1003_CR18","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/j.humpath.2013.03.010","volume":"44","author":"A Cimino-Mathews","year":"2013","unstructured":"Cimino-Mathews A, Ye X, Meeker A, Argani P, Emens LA. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Hum Pathol. 2013;44(10):2055\u201363.","journal-title":"Hum Pathol"},{"issue":"12","key":"1003_CR19","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1111\/cas.13101","volume":"107","author":"R Ogiya","year":"2016","unstructured":"Ogiya R, Niikura N, Kumaki N, Bianchini G, Kitano S, Iwamoto T, et al. Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. Cancer Sci. 2016;107(12):1730\u20135.","journal-title":"Cancer Sci"},{"key":"1003_CR20","volume-title":"Relationship between tumor infiltrating lymphocyte levels and response to pembrolizumab in metastatic triple-negative breast cancer: results from Keynote-086 trial","author":"S Loi","year":"2017","unstructured":"Loi S, Adams S, Schmid P, Cortes J, Cescon D, Winer E, et al. Relationship between tumor infiltrating lymphocyte levels and response to pembrolizumab in metastatic triple-negative breast cancer: results from Keynote-086 trial. 2017. Presented at: European Society of Medical Oncology (ESMO) 2017 Congress; Madrid, Spain: September 8\u201312, 2017. Abstract LBA13"},{"issue":"6","key":"1003_CR21","doi-asserted-by":"publisher","first-page":"e1153208","DOI":"10.1080\/2162402X.2016.1153208","volume":"5","author":"B Sobottka","year":"2016","unstructured":"Sobottka B, Pestalozzi B, Fink D, Moch H, Varga Z. Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases. Oncoimmunology. 2016;5(6):e1153208.","journal-title":"Oncoimmunology"},{"issue":"6","key":"1003_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","volume":"24","author":"S Hendry","year":"2017","unstructured":"Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international Immuno-oncology biomarkers working group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol. 2017;24(6):311\u201335.","journal-title":"Adv Anat Pathol"},{"key":"1003_CR23","doi-asserted-by":"crossref","unstructured":"Schmid P, Cruz C, Braiteh F, Eder J, Tolaney S, Kuter I, et al. Atezolizumab in metastatic TNBC: long-term clinical outcomes and biomarker analyses. Presented at AACR Annual Meeting 2017, April 1\u20135, 2017; Washington, DC, USA.","DOI":"10.1158\/1538-7445.AM2017-2986"},{"issue":"1","key":"1003_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1158\/2159-8290.CD-16-0502","volume":"7","author":"N Svoronos","year":"2017","unstructured":"Svoronos N, Perales-Puchalt A, Allegrezza MJ, Rutkowski MR, Payne KK, Tesone AJ, et al. Tumor cell-independent estrogen signaling drives disease progression through mobilization of myeloid-derived suppressor cells. Cancer Discov. 2017;7(1):72\u201385.","journal-title":"Cancer Discov"},{"key":"1003_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2016.03.011","volume":"46","author":"MV Dieci","year":"2016","unstructured":"Dieci MV, Griguolo G, Miglietta F, Guarneri V. The immune system and hormone-receptor positive breast cancer: is it really a dead end? Cancer Treat Rev. 2016;46:9\u201319.","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"1003_CR26","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1172\/JCI31942","volume":"117","author":"A Gilhar","year":"2007","unstructured":"Gilhar A, Paus R, Kalish RS. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest. 2007;117(8):2019\u201327.","journal-title":"J Clin Invest"},{"issue":"3","key":"1003_CR27","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/jid.2013.368","volume":"134","author":"X Wang","year":"2014","unstructured":"Wang X, Marr AK, Breitkopf T, Leung G, Hao J, Wang E, et al. Hair follicle mesenchyme-associated PD-L1 regulates T-cell activation induced apoptosis: a potential mechanism of immune privilege. J Invest Dermatol. 2014;134(3):736\u201345.","journal-title":"J Invest Dermatol"},{"key":"1003_CR28","doi-asserted-by":"crossref","unstructured":"Adams S, Diamond J, Hamilton E. Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). Presented at ASCO Annual Meeting 2016, Chicago, Il, USA, Abstract 1009.","DOI":"10.1200\/JCO.2016.34.15_suppl.1009"},{"key":"1003_CR29","doi-asserted-by":"crossref","unstructured":"Adams S, Schmid P, Rugo H, Winer E, Loirat D, awada A, et al. Phase 2 study of pembrolizumab montherapy for previously treated metastatic triple-negative breast cancer: KEYNOTE-086 cohort A. Presented at ASCO 2017, Chicago, Il, USA, Abstract 1008.","DOI":"10.1200\/JCO.2017.35.15_suppl.1008"},{"key":"1003_CR30","doi-asserted-by":"crossref","unstructured":"Adams S, Loi S, Toppmeyer D, Cescon D, De Laurentis M, Nanda R, et al. Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-neative breast cancer: Preliminary data from Keynote-086 cohort B. Presented at ASCO 2017, Chicago, Il, USA, Abstract 108.","DOI":"10.1200\/JCO.2017.35.15_suppl.1088"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-018-1003-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13058-018-1003-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-018-1003-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T19:07:20Z","timestamp":1561144040000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-018-1003-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,22]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1003"],"URL":"https:\/\/doi.org\/10.1186\/s13058-018-1003-1","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,22]]},"assertion":[{"value":"2 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research has been conducted in accordance with the Declaration of Helsinki. The study protocol has been approved by the Ethics Committee of Istituto Oncologico Veneto IRCCS of Padova and the Ethics Committee of Modena University Hospital. Patients signed the informed consent form.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"62"}}